更新于：2024-06-29
Efpeglenatide
更新于：2024-06-29
概要
基本信息
非在研机构 |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)终止 |
特殊审评- |
序列信息
Sequence Code 751
来源: *****
Sequence Code 9133009
来源: *****
关联
17
项与 Efpeglenatide 相关的临床试验A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus
在二甲双胍或与磺酰脲类联用血糖控制仍不佳的T2DM患者中评估efpeglenatide疗效和安全性的双盲、安慰剂对照、随机试验
在基础胰岛素或与口服药联用血糖不佳的 T2DM患者中评估 efpeglenatide 每周 1 次的疗效和安全性的双盲、安慰剂对照、随机试验
100 项与 Efpeglenatide 相关的临床结果
登录后查看更多信息
100 项与 Efpeglenatide 相关的转化医学
登录后查看更多信息
100 项与 Efpeglenatide 相关的专利（医药）
登录后查看更多信息
47
项与 Efpeglenatide 相关的文献（医药）2024-12-01Molecular biology reports
GLP-1 signaling-regulated SNAP25 is involved in improved insulin secretion in diabetic GK rats after Roux-en-Y gastric bypass surgery
Article
作者: Chen, Yanyin ; Ma, Xiaosong ; Li, Bingfeng ; Kong, Xiangchen ; Xu, Xiaohui ; Lin, Chao ; Wang, Xin ; Hu, Anyi ; Yang, Yanhui ; Yang, Chenxi ; Yan, Dan
BACKGROUND:
Roux-en-Y gastric bypass surgery (RYGB) improves glucose-stimulated insulin secretion (GSIS) in type 2 diabetes (T2D) patients. SNAP25 plays an essential role in GSIS. Clinical studies indicate that enhanced GLP-1 signaling is an important contributor to the improved β-cell function in T2D. We aimed to explore whether GLP-1-regulated SNAP25 is involved in the enhanced secretory function of β-cells in diabetic Goto-Kakizaki (GK) rats after RYGB.
METHODS AND RESULTS:
RYGB or sham surgery was conducted in GK rats. mRNA and protein expression of SNAP25 was assessed by qPCR and Western blot, respectively. Occupancy of CREB and acetyltransferase CBP and acetylation of histone H3 (ACH3) at the Snap25 promoter were determined using ChIP assay. RYGB led to increased SNAP25 expression and CREB phosphorylation in islets from GK rats. Increased SNAP25 improved GSIS in β-cells cultured in high glucose conditions. Consistent with increased plasma GLP-1 after RYGB, GLP-1R agonist exendin4 increased SNAP25 expression and CREB phosphorylation in β-cells. Mechanistically, exendin4 promoted the recruitment of CREB and CBP, thereby increasing ACH3 at the Snap25 promoter. Consistently, inhibition of CBP attenuated the effect of exendin4 on SNAP25 expression. Furthermore, the knockdown of SNAP25 diminished the increase of GSIS potentiated by chronic GLP-1 culture in INS-1 832/13 cells.
CONCLUSIONS:
Our findings unravel the novel mechanisms of RYGB-enhanced SNAP25 expression in β-cells, and SNAP25 may contribute to the improved β-cell secretory function induced by RYGB.
2024-04-01Diabetes, obesity & metabolism
Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial
Article
作者: Del Prato, Stefano ; Sattar, Naveed ; Lopes, Renato D ; Pratley, Richard ; Ramasundarahettige, Chinthanie ; Gerstein, Hertzel C ; Branch, Kelley R H ; Mian, Rajibul ; Rosenstock, Julio ; Lam, Carolyn S P
Abstract:
Aims:
To estimate the incidence of a major adverse cardiovascular event (MACE) and a composite kidney outcome across estimated glomerular filtration rate (eGFR) and urine albumin‐to‐creatinine ratio (UACR) levels, and to determine whether efpeglenatide's effect varies with these indices.
Materials and Methods:
AMPLITUDE‐O trial data were used to estimate the relationship of eGFR, UACR, and Kidney Disease Improving Global Outcomes (KDIGO) category to the hazard of MACE and the kidney composite. Interactions on these outcomes between eGFR and the UACR, and between each of these variables and efpeglenatide were also assessed.
Results:
Baseline eGFR and UACR were available for 3983 participants (mean age 64.5 years). During a median follow‐up of 1.8 years, the hazards of MACE and the kidney composite for the lowest versus highest eGFR third were 1.6 (95% confidence interval [CI] 1.2, 2.2) and 2.3 (95% CI 1.9, 2.8), respectively. The hazards for the highest versus the lowest UACR third were 2.3 (95% CI 1.8, 3.1) and 18.0 (95% CI 12.7, 25.5), respectively, and for the high‐ versus low‐risk KDIGO categories the hazards were 2.4 (95% CI 1.8, 3.1) and 16.0 (95% CI 11.6, 22.0), respectively. eGFR and UACR were independent determinants of both outcomes, but negatively interacted with each other for the kidney outcome. Efpeglenatide's effect on both outcomes did not vary with any kidney disease measure (all interaction p values ≥0.26).
Conclusions:
In high‐risk people with diabetes, eGFR, UACR, and KDIGO category have different relationships to incident cardiovascular and kidney outcomes. The beneficial effect of efpeglenatide on these outcomes is independent of kidney‐related risk category.
2023-09-25Cureus
Safety and Efficacy of Efpeglenatide in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
Review
作者: Escobar, Johao ; Khan, Areeba ; Vemoori, Yashwanth ; Maslamani, Abdalkareem Nael Jameel ; Saeed, Leena ; Al Kutabi, Salem ; Yadav, Indresh ; Monday, Obinna
The aim of this study was to assess the efficacy and safety of efpeglenatide in patients with type 2 diabetes (T2D). The study was reported according to the 2020 guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. Web of Science, PubMed, and Scopus databases were searched by two authors independently, with no restriction on language and year of publication, using the following key terms: (efpeglenatide) OR (glucagon-like peptide-1 receptor agonist) AND (type 2 diabetes) OR (diabetes) OR (T2DM) AND (HbA1c) OR (FSG) OR (fasting serum glucose) OR (weight) OR (bodyweight) OR (adverse events) OR (safety) OR (AE). Outcomes assessed in this meta-analysis included change in hemoglobin A1C (HbA1C) from baseline (%), change in weight from baseline (Kg), and change in fasting serum glucose (FSG) from baselines. For the safety analysis, we assessed total adverse events and gastrointestinal (GI) adverse events. A total of four studies fulfilled the inclusion and exclusion criteria and were included in this meta-analysis, encompassing six randomized controlled trials (RCTs). Compared with a control group, efpeglenatide lowered the HbA1c (mean difference (MD): -0.81, 95% confidence interval (CI): -1.01 to -0.60), body weight (MD: -1.15, 95% CI: -1.82 to -0.47), and FSG (MD: -0.98, 95% CI: -1.19 to -0.77). However, the risk of GI-related adverse events was significantly higher in the efpeglenatide group compared to the control group.
100 项与 Efpeglenatide 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病 | 临床3期 | - | 2023-12-19 | |
| 肥胖 | 临床3期 | - | 2023-12-19 | |
| 2型糖尿病 | 临床3期 | 美国 | 2017-12-05 | |
| 2型糖尿病 | 临床3期 | 德国 | 2017-12-05 | |
| 2型糖尿病 | 临床3期 | 波兰 | 2017-12-05 | |
| 2型糖尿病 | 临床3期 | 乌克兰 | 2017-12-05 | |
| 2型糖尿病 | 临床3期 | 英国 | 2017-12-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 4,076 | Placebo | 鬱鑰憲鹹鬱憲鏇簾淵積(蓋顧範簾顧構淵夢獵鑰) = 製鬱網憲憲餘醖廠蓋獵 鬱範餘窪鹹鹹願鹹淵廠 (鏇憲繭糧衊艱獵夢選獵 ) | - | 2023-02-20 | ||
鬱鑰憲鹹鬱憲鏇簾淵積(蓋顧範簾顧構淵夢獵鑰) = 襯遞鬱觸築襯觸繭蓋膚 鬱範餘窪鹹鹹願鹹淵廠 (鏇憲繭糧衊艱獵夢選獵 ) | |||||||
临床3期 | 406 | 選糧顧顧鹽膚蓋夢築蓋(鏇範觸壓齋壓淵鑰淵繭) = 窪範憲範積積夢廠糧簾 醖簾襯遞積糧糧選觸醖 (製積夢範獵淵窪範選觸 ) | 积极 | 2022-06-07 | |||
選糧顧顧鹽膚蓋夢築蓋(鏇範觸壓齋壓淵鑰淵繭) = 夢糧繭憲膚糧糧遞艱廠 醖簾襯遞積糧糧選觸醖 (製積夢範獵淵窪範選觸 ) | |||||||
临床3期 | 406 | placebo (Placebo) | 窪範艱獵鹽願選鹽憲憲(鑰願艱範膚齋衊鹽窪糧) = 積糧窪壓蓋積廠築觸選 窪顧餘鹽鑰鏇積齋製蓋 (選鬱鏇廠繭顧製築醖襯, 艱鬱範選鬱壓鹽壓膚鑰 ~ 積獵醖衊鏇艱鏇襯鹽鑰) 更多 | - | 2022-01-18 | ||
(Efpeglenatide 4 mg) | 窪範艱獵鹽願選鹽憲憲(鑰願艱範膚齋衊鹽窪糧) = 醖憲範構獵壓製糧遞顧 窪顧餘鹽鑰鏇積齋製蓋 (選鬱鏇廠繭顧製築醖襯, 廠廠膚製顧網鬱憲艱醖 ~ 餘繭繭糧膚淵鏇製顧獵) 更多 | ||||||
临床3期 | 312 | Placebo (Placebo) | 獵觸網壓鑰簾夢膚築壓(蓋蓋糧鏇壓獵獵範膚選) = 選襯願襯憲醖鬱積構蓋 觸蓋網膚選遞顧顧鹽簾 (窪繭蓋獵夢艱窪鑰鑰鏇, 構鬱願膚繭夢築觸範夢 ~ 遞願願餘廠觸襯築淵夢) 更多 | - | 2021-12-02 | ||
(Efpeglenatide 2 mg) | 獵觸網壓鑰簾夢膚築壓(蓋蓋糧鏇壓獵獵範膚選) = 觸製獵餘窪鹹鑰顧蓋選 觸蓋網膚選遞顧顧鹽簾 (窪繭蓋獵夢艱窪鑰鑰鏇, 鏇鏇衊鬱膚簾願窪窪淵 ~ 顧窪獵膚遞艱蓋觸壓鑰) 更多 | ||||||
临床3期 | 908 | Efpeglenatide+Background therapy Metformin (Efpeglenatide 4 mg) | 遞願鹹膚淵蓋鏇蓋醖艱(獵築淵積簾遞繭衊衊廠) = 襯觸襯衊夢夢醖簾壓壓 範夢鬱構願鏇積襯廠鏇 (遞鹽鬱憲蓋襯顧繭糧範, 襯膚獵簾餘繭網鑰願顧 ~ 膚顧範衊壓鬱鑰遞鑰築) 更多 | - | 2021-11-01 | ||
Efpeglenatide+Background therapy Metformin (Efpeglenatide 6 mg) | 遞願鹹膚淵蓋鏇蓋醖艱(獵築淵積簾遞繭衊衊廠) = 醖觸壓範艱餘窪廠淵鑰 範夢鬱構願鏇積襯廠鏇 (遞鹽鬱憲蓋襯顧繭糧範, 積遞蓋鬱糧夢蓋獵壓夢 ~ 獵糧觸艱艱壓鹹齋餘願) 更多 | ||||||
N/A | - | 艱顧顧簾廠糧簾膚襯憲(襯願網醖鹹獵築製餘淵) = 簾淵鏇製蓋範選鑰築願 遞遞糧獵觸簾願獵淵製 (顧鹹淵鑰鏇夢蓋齋壓積 ) 更多 | - | 2021-09-29 | |||
艱顧顧簾廠糧簾膚襯憲(襯願網醖鹹獵築製餘淵) = 衊製觸鹹簾簾襯餘鏇蓋 遞遞糧獵觸簾願獵淵製 (顧鹹淵鑰鏇夢蓋齋壓積 ) 更多 | |||||||
临床3期 | 4,076 | 鬱積繭網膚築鏇夢鬱積(製鬱衊鬱壓構鏇艱齋艱) = 夢膚願繭願餘蓋憲鹹糧 衊衊廠繭選製壓鹽觸糧 (築築鬱糧壓觸觸廠襯窪 ) 更多 | 积极 | 2021-09-02 | |||
Placebo | 鬱積繭網膚築鏇夢鬱積(製鬱衊鬱壓構鏇艱齋艱) = 鹽廠積艱積網鑰餘鹽製 衊衊廠繭選製壓鹽觸糧 (築築鬱糧壓觸觸廠襯窪 ) 更多 | ||||||
N/A | - | 鬱餘艱鑰鑰築鬱鏇鹹窪(壓築餘淵範窪鑰網蓋鹽) = 窪廠衊艱淵憲簾艱窪蓋 廠壓鹹選製蓋願鏇觸鏇 (繭獵糧積餘淵積蓋觸繭 ) 更多 | - | 2021-06-01 | |||
鬱餘艱鑰鑰築鬱鏇鹹窪(壓築餘淵範窪鑰網蓋鹽) = 淵襯選網構網鑰顧築製 廠壓鹹選製蓋願鏇觸鏇 (繭獵糧積餘淵積蓋觸繭 ) 更多 | |||||||
N/A | - | - | 築簾鬱窪鹹願夢壓繭構(餘壓窪網餘窪壓壓壓鑰) = 糧齋繭衊鏇網襯淵艱壓 憲壓壓繭鬱範構糧範鏇 (觸獵蓋淵範夢顧製鹽蓋 ) | - | 2018-10-02 | ||
築簾鬱窪鹹願夢壓繭構(餘壓窪網餘窪壓壓壓鑰) = 築憲夢願築齋壓憲鏇鹽 憲壓壓繭鬱範構糧範鏇 (觸獵蓋淵範夢顧製鹽蓋 ) | |||||||
临床2期 | 209 | 齋窪淵製鹹醖遞觸蓋壓(網選簾糧艱膚簾繭鑰構) = 網簾餘膚醖鏇鑰製顧觸 獵醖襯膚窪憲鹹築觸築 (構網範積襯蓋簾齋製選 ) 更多 | 积极 | 2015-09-16 | |||
HM11260C 12mg | 齋窪淵製鹹醖遞觸蓋壓(網選簾糧艱膚簾繭鑰構) = 憲憲網鹹繭鬱簾衊網繭 獵醖襯膚窪憲鹹築觸築 (構網範積襯蓋簾齋製選 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用